Georgia's Online Cancer Information Center

Find A Clinical Trial

A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors

Status
Completed
Cancer Type
Solid Tumor
Trial Phase
Phase I
Eligibility
18 Years and older, Male and Female
Study Type
Treatment
NCT ID
NCT01733004
Protocol IDs
MM-141-01-01-01 (primary)
Study Sponsor
Merrimack Pharmaceuticals

Summary

This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design, evaluating MM-141 at varying dose levels and frequencies.

Eligibility

  1. Advanced malignant solid tumors for which no curative therapy exists that has recurred or pgrogressed following standard therapy
  2. Eighteen years of age or above
  3. Able to understand and sign an informed consent (or have a legal representative who is able to do so)
  4. Measurable disease according to RECIST v1.1
  5. ECOG Performance Score of 0 or 1
  6. Adequate bone marrow, hepatic, renal and cardiac function
  7. Willing to abstain from sexual intercourse or to use an effective form of contraception during the study and for 90 days following the last dose of MM-141
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Georgia CORE

 

Georgia CORE bridges the gap between groundbreaking research, educational outreach, and effective advocacy to transform the landscape of cancer care for all Georgians.